Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of Alpha Klotho mRNA (aKL003) in Healthy Older Adults
NCT07544420Phase 1Not yet recruiting
- Sponsor
- Klothea Bio
- Start
- May 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in aging (2 arms), sponsored by Klothea Bio. Primary endpoints: Incidence and severity of unsolicited adverse events at Day 60 and Incidence and severity of solicited reactogenicity events at Day 60. Planned start May 2026; status: not yet recruiting.
02
Conditions
aging
Beyond the preview
Go deeper on NCT07544420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544420.